Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Roche Licenses ProBioGen’s GlymaxX Technology | Contract Pharma

What are you searching for?

Sign in
Breaking News

Roche Licenses ProBioGen’s GlymaxX Technology

ADCC-enhancement will be applied to innovative cancer therapy

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

ProBioGen AG has signed a commercial license agreement with Roche to apply ProBioGen’s GlymaxX technology to boost the antibody’s ADCC anti-tumor activity.
 
The GlymaxX technology for production of afucosylated proteins is universally applicable, simple and potent. The advantage of the GlymaxX technology is that a single GlymaxX modified cell line is sufficient to produce both, completely fucosylated or afucosylated antibodies and those with an intermediate defined fuscosylation level. The technology can be integrated in newly developed or already existing cell lines of different origins.
 
ProBioGen specializes in developing and manufacturing complex therapeutic glycoproteins. The GlymaxX technology prevents the addition of the sugar “fucose” to the N-linked antibody carbohydrate part by antibody producing cells. The absence of fucose enhances ADCC (antibody-dependent cell-mediated cytotoxicity) activity for antibodies directed against cancer and infectious diseases. 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics